Overview

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Status:
Recruiting
Trial end date:
2022-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC